NERV — Minerva Neurosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $260.51m
- $238.21m
Annual cashflow statement for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -49.9 | -32.1 | -30 | 1.44 | -293 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 26.8 | 11.5 | 10.3 | -20.7 | 281 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.259 | -4.06 | 4.94 | -0.321 | -0.632 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -24.6 | -24.6 | -14.8 | -19.6 | -13.5 |
| Capital Expenditures | — | -0.016 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | 0 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | -0.016 | 0 | 0 | 0 |
| Financing Cash Flow Items | 60 | 0 | -0.396 | — | -5.55 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 60 | -0 | 19.6 | — | 74.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35.4 | -24.7 | 4.82 | -19.6 | 60.9 |